Could a short course of antiviral drugs stop hepatitis b passing from mother to child?

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all newborns receive the hepatitis B vaccine starting at birth. The study focuses on women at highest risk of passing the virus—those with a positive HBeAg test or very high viral load—and will check if the babies are still virus-free at 9 to 12 months old.